Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis
Seminars in Cancer Biology · 2026-09 · 125 · 75-87
DOI: 10.1016/j.semcancer.2026.07.004 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Seminars in Cancer Biology, 2026-09. Verfasst von Marilina García-Aranda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research and Innovation Unit, Hospital Universitario Costa del Sol, Autovía A-7 km 187, Marbella 29603, Spain; Group of Translational Research in Can…. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carlos III Health Institute, Government of Andalusia Andalusian Health Service, Caixabank SA.
Abstract (Originalsprache)
BACKGROUND: Oligometastatic and oligoprogressive disease treated with stereotactic ablative radiotherapy (SABR) represents a clinically heterogeneous entity. Increasing evidence suggests that anatomical definitions alone may not adequately capture underlying biological diversity. This systematic review aimed to synthesize translational evidence exploring evolutionary dynamics, resistance mechanisms, and biomarker-driven stratification in patients treated with SABR. METHODS: A systematic literature review was performed including prospective and retrospective studies evaluating translational biomarkers in oligometastatic or oligoprogressive settings treated with SABR. Studies assessing genomic, transcriptomic, circulating or immune-related biomarkers were included. Data were summarized qualitatively according to predefined translational domains: (i) evolutionary dynamics under systemic therapy pressure, (ii) baseline biological stratification, (iii) longitudinal circulating biomarkers, and (iv) systemic immune remodeling. Exploratory quantitative visual syntheses were performed using reported hazard ratios when conceptually comparable endpoints were available. RESULTS: 19 studies comprising 1527 patients were included. Across tumor types and treatment contexts, translational analyses consistently indicated that anatomically defined oligometastatic states encompass biologically distinct subgroups with different risks of systemic progression. Studies evaluating oligoprogression under ongoing systemic therapy suggested a distinction between spatially constrained resistance and systemic molecular escape, supported by circulating tumor DNA and tissue- or plasma-based molecular profiling (including genomic and transcriptomic analyses). Baseline biological features, including adverse genomic signatures and circulating biomarkers, were associated with inferior progression outcomes despite metastasis-directed therapy. Longitudinal biomarkers provided early signals of treatment response and systemic control. Immune remodeling after SABR showed context-dependent effects, both systemic immune activation and treatment-related immunosuppression reported across studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Innovation Unit, Hospital Universitario Costa del Sol, Autovía A-7 km 187, Marbella 29603, Spain; Group of Translational Research in Cancer and Other Prevalent Diseases (B-14), IBIMA Plataforma BIONAND, Mal…
- Department of Radiation Oncology, Virgen de La Victoria University Hospital, Malaga, Spain; Group of Translational Research in Cancer Immunotherapy and Epigenetics (B-05), IBIMA Plataforma BIONAND, Malaga, Spain.
- Group of Translational Research in Cancer Immunotherapy and Epigenetics (B-05), IBIMA Plataforma BIONAND, Malaga, Spain; Department of Medical Oncology, Virgen de La Victoria University Hospital, Malaga, Spain.
- Group of Translational Research in Cancer Immunotherapy and Epigenetics (B-05), IBIMA Plataforma BIONAND, Malaga, Spain; Department of Medical Oncology, Virgen de La Victoria University Hospital, Malaga, Spain; Precisio…
Förderung
- Carlos III Health Institute
- Government of Andalusia Andalusian Health Service
- Caixabank SA
- Spanish Association Against Cancer Scientific Foundation
- European Commission
- National Plan for Scientific and Technical Research and Innovation
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
García-Aranda, M., Zafra-Martín, J., Rodríguez-Martínez, A., Rueda-Domínguez, A., & Barragán, I. (2026). Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis. Seminars in Cancer Biology, 125, 75-87. https://doi.org/10.1016/j.semcancer.2026.07.004
Vancouver
García-Aranda M, Zafra-Martín J, Rodríguez-Martínez A, Rueda-Domínguez A, Barragán I. Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis. Seminars in Cancer Biology. 2026;125:75-87. doi:10.1016/j.semcancer.2026.07.004
BibTeX
@article{GarcaAranda2026,
author = {García-Aranda, Marilina and Zafra-Martín, Juan and Rodríguez-Martínez, Alba and Rueda-Domínguez, Antonio and Barragán, Isabel},
title = {Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis},
journal = {Seminars in Cancer Biology},
year = {2026},
volume = {125},
pages = {75--87},
doi = {10.1016/j.semcancer.2026.07.004}
}
EUVIMED